Comparative Pharmacology
Head-to-head clinical analysis: EVOMELA versus HEXALEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVOMELA versus HEXALEN.
EVOMELA vs HEXALEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EVOMELA (melphalan) is a bifunctional alkylating agent that forms cross-links between DNA strands, inhibiting DNA replication and transcription, leading to cell death.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, and inducing apoptosis in rapidly dividing cells.
140-200 mg/m² IV over 30 minutes for conditioning prior to ASCT; off-label: 16 mg/m² IV over 15-20 minutes every 4 weeks for MM.
260 mg/m2/day orally in 4 divided doses for 14 or 21 days of a 28-day cycle.
None Documented
None Documented
Terminal elimination half-life is approximately 75 minutes (range 40-120 minutes) in patients with normal renal function; prolonged to 180-300 minutes in renal impairment
Terminal elimination half-life is 12-13 hours; prolonged to 24 hours in renal impairment.
Primarily renal: approximately 10-30% of unchanged drug excreted in urine within 24 hours; extensive hepatic metabolism; fecal excretion accounts for <5%
Primarily renal and hepatic metabolism; 60-70% excreted in urine as unchanged drug and metabolites; 15-20% eliminated in feces via biliary secretion.
Category C
Category C
Alkylating Agent
Alkylating Agent